EDAP TMS SA - Asset Resilience Ratio
EDAP TMS SA (EDAP) has an Asset Resilience Ratio of 73.58% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check EDAP PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2023)
This chart shows how EDAP TMS SA's Asset Resilience Ratio has changed over time. See EDAP equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down EDAP TMS SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of EDAP TMS SA.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $60.46 Million | 73.58% |
| Total Liquid Assets | $60.46 Million | 73.58% |
Asset Resilience Insights
- Very High Liquidity: EDAP TMS SA maintains exceptional liquid asset reserves at 73.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
EDAP TMS SA Industry Peers by Asset Resilience Ratio
Compare EDAP TMS SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
China National Medicines Corp Ltd
SHG:600511 |
Medical Distribution | 0.04% |
|
Cyclopharm Ltd
AU:CYC |
Medical Distribution | 1.98% |
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.21% |
Annual Asset Resilience Ratio for EDAP TMS SA (2000–2023)
The table below shows the annual Asset Resilience Ratio data for EDAP TMS SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 95.05% | $87.01 Million | $91.55 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $53.07 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $48.74 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $46.90 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $46.59 Million | -- |
| 2015-12-31 | 2.59% | $1.00 Million | $38.58 Million | -0.52pp |
| 2014-12-31 | 3.11% | $1.00 Million | $32.15 Million | -0.61pp |
| 2013-12-31 | 3.72% | $1.00 Million | $26.87 Million | +0.32pp |
| 2012-12-31 | 3.40% | $1.04 Million | $30.44 Million | -1.43pp |
| 2011-12-31 | 4.83% | $1.57 Million | $32.55 Million | +0.60pp |
| 2010-12-31 | 4.23% | $1.52 Million | $35.94 Million | +1.47pp |
| 2009-12-31 | 2.76% | $1.11 Million | $40.38 Million | +0.15pp |
| 2008-12-31 | 2.61% | $1.14 Million | $43.86 Million | +0.19pp |
| 2007-12-31 | 2.42% | $1.09 Million | $45.07 Million | -0.76pp |
| 2006-12-31 | 3.18% | $1.03 Million | $32.47 Million | +2.97pp |
| 2002-12-31 | 0.21% | $81.95K | $39.82 Million | -18.03pp |
| 2001-12-31 | 18.24% | $9.70 Million | $53.21 Million | -24.82pp |
| 2000-12-31 | 43.06% | $21.71 Million | $50.43 Million | -- |
About EDAP TMS SA
EDAP TMS S.A., a medical technology company, engages in the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment de… Read more